BioXmark® has the potential to improve radiotherapy precision and therapy outcome.
BioXmark® is a liquid ready-to-inject fiducial marker visible on X-ray, CBCT, CT, MRI and ultrasonography.
It is provided as a sterile, transparent solution in ampoules containing 1mL each. It has a low initial viscosity. Once injected into soft tissue, a highly viscous fiducial marker is formed.
BioXmark® has a range of appealing properties compared to metal based markers currently used in the clinic:
- Injected with no change in current equipment or procedures
- Can be injected using thin needles (≤25G) either percutaneously or using an endoscope assisted injection method (EUS, EBUS etc.)
- The size of the marker can be controlled based on the injection volume
- Numerous markers in one ampoule. Visible on CBCT at volume of 10µL and larger
- Visible in all relevant imaging modalities (X-ray, CBCT, CT, MRI and ultrasonography)
- No sharp edges and glue-like character limits migration
- Low degree of beam hardening artifacts compared to metal based fiducial markers despite providing approximately 1,000HU of contrast
- Very low Z-value and hence low impact on dose perturbation, making it an ideal fiducial marker for proton therapy
- Slow biodegradation with no relevant change of size during the first 3 months after injection
The properties of BioXmark® has been verified in both animal models and in clinical trials.
Radiotherapy is the most cost-effective treatment modality for many cancers, and nearly two-thirds of all cancer patients receive radiotherapy as a part of their treatment.
The main challenge in radiotherapy is to administer a sufficiently high dose to the cancer cells with minimal damage to the surrounding healthy tissue. Tumor motion and inadequate patient set-up are two important factors, which constitute this challenge.
Image-guided radiation therapy (IGRT) is a method of radiation therapy that incorporates imaging techniques during each treatment session. IGRT is employed to mitigate errors derived from tumor motion and inadequate patient set-up. The benefits of IGRT includes:
- Accurate delivery of radiation
- Improved definition, localization and monitoring of tumor position, size and shape before and during treatment
- The possibility of higher, targeted radiation dosage to improve tumor control
- Decreased radiation exposure to normal tissue surrounding the tumor
IGRT requires use of frequent imaging and good visibility of tumors and organs at risks. However, soft tissue targets are most often not visible on x-ray images due to a very low tumor to tissue contrast ratio. Hence, soft tissue markers are placed in proximity to the tumor to work as an accurate surrogate.